A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors

Brief description of study

If you have been diagnosed with selected advanced or recurrent solid tumors including bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell histology, head and neck cancer, melanoma, prostate cancer, malignant pleural mesothelioma, and non-small cell lung cancer, you may qualify to participate in a research study of an experimental drug, GSK3359609.  The main goals of this Phase I trial is to determine the safety and tolerability of the experimental drug GSK3359609 in combination with pembrolizumab; Evaluate whether your body produces antibodies against GSK3359609 and pembrolizumab in combination; and the possible biological substance/proteins in your blood and/or tumor tissue that may signal that the drugs are having an effect or predict which patients may benefit from treatment with GSK3359609 in combination with pembrolizumab.

Clinical Study Identifier: s16-01816
ClinicalTrials.gov Identifier: NCT02723955

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.